



BRITISH COLUMBIA  
CENTRE *for* EXCELLENCE  
*in* HIV/AIDS

# BC HIV Treatment Program

Monthly Report  
**June 2025**



## FOREWORD

The British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) is a provincial treatment and research program, with the mandate to improve the health of people living with HIV (“PLWH”), and those at elevated risk of acquiring HIV in British Columbia (BC), by advancing and promoting programs for treatment and prevention of HIV, and related conditions, guided by Treatment as Prevention® (TasP®) principles. Funded by the BC’s Ministry of Health, through the province’s PharmaCare Program, the BC-CfE’s Drug Treatment Programs provide medications for HIV treatment, prevention, and select related conditions, at no charge, to medically eligible BC residents living with HIV, or at elevated risk of HIV acquisition. The provision of these medications are based on guidelines developed by the BC-CfE’s Committee for Drug Evaluation and Therapy (CDET) and program consideration.

A key component of the BC-CfE’s mandate is to monitor and evaluate its HIV Treatment Program, reporting on a regular basis and providing essential information to BC’s health authorities, treating clinicians, and the community at large. This HIV Treatment Program Report provides an overview of the use of antiretroviral medications in BC for the treatment of HIV, common drug combinations, key monitoring parameters, and distribution of program participants throughout the province.

Figures and graphs in this document are best viewed in colour.

Please note that any comments or queries regarding this report should be forwarded to [info@bccfe.ca](mailto:info@bccfe.ca).

### BC Centre for Excellence in HIV/AIDS Drug Treatment Programs

St. Paul’s Hospital  
687 - 1081 Burrard Street  
Vancouver, BC  
V6Z 1Y6

Tel: 604.806.8515  
Fax: 604.806.9044

Website: [www.bccfe.ca](http://www.bccfe.ca)  
Email: [info@bccfe.ca](mailto:info@bccfe.ca)

Funding for the BC Centre for Excellence in HIV/AIDS is provided through BC’s PharmaCare and Ministry of Health.

**DISCLAIMER:** All information presented in this report is generated from a secure, live database maintained by the BC-CfE. Privacy and confidentiality are matters which are taken very seriously and strict rules and procedures are applied to ensure that the information stored is secure.

Figures and tables provided in this report represent the best estimates at the time the document was generated, and may be subject to change. Please be advised that the information in this document is provided in good faith and is derived from sources understood to be accurate and up-to-date at the report’s date of publication.

© 2026 BC Centre for Excellence in HIV/AIDS



## TABLE OF CONTENTS

### 1. List of Figures

- 1.1 Distribution of Participants on Antiretroviral Treatment in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV Treatment Program by Regimen Category
- 1.3 Distribution of Participants in HIV Treatment Program by Regimen Category
- 1.4 Distribution of Participants on Nucleos(t)ide Analogue Reverse Transcriptase Inhibitors by INGREDIENT
- 1.5 Number of Participants on Nucleos(t)ide Analogue Reverse Transcriptase Inhibitors by INGREDIENT
- 1.6 Distribution of Participants on Protease Inhibitors by INGREDIENT
- 1.7 Number of Participants on Protease Inhibitors by INGREDIENT
- 1.8 Distribution of Participants on Non-Nucleoside Analogue Reverse Transcriptase Inhibitors by INGREDIENT
- 1.9 Number of Participants on Non-Nucleoside Analogue Reverse Transcriptase Inhibitors by INGREDIENT
- 1.10 Distribution of Participants on Integrase Inhibitors by INGREDIENT
- 1.11 Number of Participants on Integrase Inhibitors by INGREDIENT
- 1.12 Distribution of Participants on Other Antiretroviral Drug Classes by INGREDIENT
- 1.13 Number of Participants on Other Antiretroviral Drug Classes by INGREDIENT
- 1.14 Distribution of Participants on Antiretroviral Treatment by Number of Antiretrovirals (graph)
- 1.15 Distribution of Participants on Antiretroviral Treatment by Number of Antiretrovirals (table)
- 1.16 Percent Distribution of Active Participants by CD4 Count
- 1.17 Distribution of Active Participants by CD4 Count
- 1.18 Initial Regimen Composition for Antiretroviral Treatment Naïve Participants Starting Treatment (graph)
- 1.19 Initial Regimen Composition for Antiretroviral Treatment Naïve Participants Starting Treatment (table)
- 1.20 Pre-entry CD4 for Antiretroviral Treatment Naïve Participants in the HIV Treatment Program (graph)
- 1.21 Pre-entry CD4 for Antiretroviral Treatment Naïve Participants in the HIV Treatment Program (table)
- 1.22 Antiretroviral Resistance by Drug Class Among Participants on Antiretroviral Treatment (graph)
- 1.23 Antiretroviral Resistance by Drug Class Among Participants on Antiretroviral Treatment (table)
- 1.24 Active Participants by number of Antiretroviral Drug Classes with Resistance (graph)
- 1.25 Active Participants by number of Antiretroviral Drug Classes with Resistance (table)

### 2. List of Tables

- 2.1 Active participants by Year of Program Initiation (1987 - 2025) - as of January 2025
- 2.2 HIV Viral Load (copies/mL) and CD4 (cells/ $\mu$ L) for Participants on Antiretroviral Treatment
- 2.3 BC-CfE HIV Treatment Program Enrolment

### 3. Distribution of HIV Treatment Program Active Participants

- 3.1 Provincial Health Authorities
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

## TABLE OF CONTENTS (continued)

### 4. Health Authority Tables

#### INTERIOR HEALTH

- 4.1 Distribution of Participants by Age & Sex at Birth
- 4.2 Distribution of Participants by Program Duration
- 4.3 Distribution of Antiretroviral Treatment Prescribers

#### FRASER HEALTH

- 4.4 Distribution of Participants by Age & Sex at Birth
- 4.5 Distribution of Participants by Program Duration
- 4.6 Distribution of Antiretroviral Treatment Prescribers

#### VANCOUVER COASTAL

- 4.7 Distribution of Participants by Age & Sex at Birth
- 4.8 Distribution of Participants by Program Duration
- 4.9 Distribution of Antiretroviral Treatment Prescribers

#### VANCOUVER ISLAND

- 4.10 Distribution of Participants by Age & Sex at Birth
- 4.11 Distribution of Participants by Program Duration
- 4.12 Distribution of Antiretroviral Treatment Prescribers

#### NORTHERN HEALTH


- 4.13 Distribution of Participants by Age & Sex at Birth
- 4.14 Distribution of Participants by Program Duration
- 4.15 Distribution of Antiretroviral Treatment Prescribers

#### INDIGENOUS PARTICIPANTS

- 4.16 Distribution of Indigenous Participants by Health Service Delivery Area and Sex at Birth



1.1 Distribution of Participants on Antiretroviral Treatment in British Columbia by Health Authority June 2025  
N = 7713




Health Authority	Male	Female	All
FRASER	1627	510	2137
VANCOUVER ISLAND	893	176	1069
VANCOUVER COASTAL	3189	441	3630
INTERIOR	501	120	621
NORTHERN	161	87	248
	<b>6371</b>	<b>1334</b>	<b>7705</b>
<b>Unknown/not stated</b>			<b>8</b>
<b>Total</b>			<b>7713</b>

On antiretroviral treatment is defined as being on treatment in the current month  
**Unknown/not stated** is defined as being on treatment in the current month, and city of residence is unknown  
**Male & Female** refer to Sex assigned at birth



1.2 Distribution of Participants in HIV Treatment Program by Regimen Category  
June 2020 - June 2025



**1.3 Distribution of Participants in HIV Treatment Program by Regimen Category**

MON-YYYY	Total	INSTI		Boosted PI		NNRTI		2 drugs from 2 classes		≥3 drugs from ≥3 classes		Other	
		n	%	n	%	n	%	n	%	n	%	n	%
JUL-2023	7577	4758	62.8	662	8.7	626	8.3	842	11.1	628	8.3	61	0.8
AUG-2023	7600	4773	62.8	643	8.5	621	8.2	864	11.4	632	8.3	67	0.9
SEP-2023	7609	4793	63.0	639	8.4	616	8.1	879	11.6	617	8.1	65	0.9
OCT-2023	7610	4808	63.2	615	8.1	611	8.0	897	11.8	618	8.1	61	0.8
NOV-2023	7612	4799	63.0	611	8.0	599	7.9	918	12.1	624	8.2	61	0.8
DEC-2023	7603	4808	63.2	593	7.8	596	7.8	936	12.3	614	8.1	56	0.7
JAN-2024	7642	4856	63.5	583	7.6	585	7.7	952	12.5	609	8.0	57	0.7
FEB-2024	7647	4861	63.6	564	7.4	586	7.7	971	12.7	609	8.0	56	0.7
MAR-2024	7636	4846	63.5	543	7.1	580	7.6	991	13.0	618	8.1	58	0.8
APR-2024	7670	4884	63.7	538	7.0	570	7.4	1000	13.0	621	8.1	57	0.7
MAY-2024	7687	4902	63.8	536	7.0	566	7.4	1023	13.3	607	7.9	53	0.7
JUN-2024	7687	4910	63.9	526	6.8	556	7.2	1033	13.4	606	7.9	56	0.7
JUL-2024	7718	4938	64.0	520	6.7	541	7.0	1060	13.7	605	7.8	54	0.7
AUG-2024	7709	4933	64.0	505	6.6	537	7.0	1081	14.0	602	7.8	51	0.7
SEP-2024	7697	4911	63.8	484	6.3	530	6.9	1124	14.6	595	7.7	53	0.7
OCT-2024	7725	4938	63.9	467	6.0	512	6.6	1167	15.1	593	7.7	48	0.6
NOV-2024	7703	4946	64.2	464	6.0	490	6.4	1176	15.3	581	7.5	46	0.6
DEC-2024	7720	4949	64.1	456	5.9	479	6.2	1199	15.5	588	7.6	49	0.6
JAN-2025	7739	4959	64.1	437	5.6	478	6.2	1234	15.9	586	7.6	45	0.6
FEB-2025	7696	4929	64.0	419	5.4	460	6.0	1264	16.4	577	7.5	47	0.6
MAR-2025	7689	4921	64.0	408	5.3	453	5.9	1291	16.8	572	7.4	44	0.6
APR-2025	7719	4947	64.1	394	5.1	432	5.6	1320	17.1	584	7.6	42	0.5
MAY-2025	7705	4911	63.7	386	5.0	423	5.5	1369	17.8	573	7.4	43	0.6
JUN-2025	7713	4893	63.4	371	4.8	417	5.4	1427	18.5	565	7.3	40	0.5

**n** is number of participants on the specified regimen class in the specified month


**%** is ratio of **n** and total number of participants on antiretroviral treatment in the specified month

**INSTI:** Integrase Inhibitor, **PI:** Protease Inhibitor, **NNRTI:** Non-Nucleoside Analogue Reverse Transcriptase Inhibitor,

**N(t)RTI:** Nucleos(t)ide Analogue Reverse Transcriptase Inhibitor



1.4 Distribution of Participants on Nucleos(t)ide Analogue Reverse Transcriptase Inhibitors by INGREDIENT  
June 2020 - June 2025




**1.5 Number of Participants on Nucleos(t)ide Analogue Reverse Transcriptase Inhibitors by INGREDIENT**

MON-YYYY	Total Participants	abacavir		emtricitabine		lamivudine		tenofovir <TAF>		tenofovir <TDF>		zidovudine	
		n	%	n	%	n	%	n	%	n	%	n	%
JUL-2023	<b>7438</b>	1966	26.4	4530	60.9	2917	39.2	3678	49.5	985	13.2	14	0.2
AUG-2023	<b>7467</b>	1935	25.9	4561	61.1	2909	39.0	3717	49.8	969	13.0	14	0.2
SEP-2023	<b>7478</b>	1910	25.5	4578	61.2	2902	38.8	3746	50.1	954	12.8	13	0.2
OCT-2023	<b>7474</b>	1895	25.4	4573	61.2	2904	38.9	3766	50.4	935	12.5	14	0.2
NOV-2023	<b>7474</b>	1866	25.0	4585	61.4	2891	38.7	3783	50.6	918	12.3	15	0.2
DEC-2023	<b>7464</b>	1831	24.5	4595	61.6	2874	38.5	3820	51.2	895	12.0	13	0.2
JAN-2024	<b>7502</b>	1831	24.4	4633	61.8	2881	38.4	3866	51.5	890	11.9	13	0.2
FEB-2024	<b>7504</b>	1795	23.9	4641	61.9	2868	38.2	3896	51.9	864	11.5	13	0.2
MAR-2024	<b>7493</b>	1759	23.5	4656	62.1	2845	38.0	3927	52.4	844	11.3	13	0.2
APR-2024	<b>7525</b>	1742	23.2	4690	62.3	2844	37.8	3968	52.7	843	11.2	13	0.2
MAY-2024	<b>7544</b>	1706	22.6	4734	62.8	2822	37.4	4018	53.3	832	11.0	12	0.2
JUN-2024	<b>7544</b>	1691	22.4	4738	62.8	2817	37.3	4047	53.7	801	10.6	13	0.2
JUL-2024	<b>7570</b>	1667	22.0	4763	62.9	2812	37.2	4077	53.9	800	10.6	13	0.2
AUG-2024	<b>7563</b>	1633	21.6	4771	63.1	2796	37.0	4097	54.2	782	10.3	13	0.2
SEP-2024	<b>7551</b>	1600	21.2	4769	63.2	2797	37.0	4113	54.5	768	10.2	13	0.2
OCT-2024	<b>7577</b>	1556	20.5	4810	63.5	2789	36.8	4170	55.0	754	10.0	13	0.2
NOV-2024	<b>7555</b>	1499	19.8	4821	63.8	2744	36.3	4193	55.5	739	9.8	11	0.2
DEC-2024	<b>7572</b>	1481	19.6	4835	63.9	2756	36.4	4223	55.8	734	9.7	11	0.2
JAN-2025	<b>7591</b>	1431	18.9	4873	64.2	2740	36.1	4273	56.3	721	9.5	10	0.1
FEB-2025	<b>7547</b>	1370	18.2	4860	64.4	2698	35.8	4280	56.7	701	9.3	8	0.1
MAR-2025	<b>7537</b>	1335	17.7	4869	64.6	2680	35.6	4312	57.2	684	9.1	8	0.1
APR-2025	<b>7557</b>	1304	17.3	4909	65.0	2664	35.3	4374	57.9	655	8.7	6	0.1
MAY-2025	<b>7537</b>	1242	16.5	4894	64.9	2654	35.2	4373	58.0	630	8.4	7	0.1
JUN-2025	<b>7540</b>	1196	15.9	4910	65.1	2647	35.1	4406	58.4	620	8.2	7	0.1

**n** is defined as number of participants on antiretroviral treatment which contains the INGREDIENT;  
**%** is calculated as ratio of "n" and number of participants whose treatment is of the given antiretroviral drug class



1.6 Distribution of Participants on Protease Inhibitors by INGREDIENT  
June 2020 - June 2025




**1.7 Number of Participants on Protease Inhibitors by INGREDIENT**

MON-YYYY	Total Participants	atazanavir		darunavir		lopinavir		ritonavir		tipranavir	
		n	%	n	%	n	%	n	%	n	%
JUL-2023	1247	283	22.7	927	74.3	38	3.1	1	0.1	1	0.1
AUG-2023	1225	276	22.5	914	74.6	36	2.9	0	0.0	0	0.0
SEP-2023	1214	271	22.3	909	74.9	35	2.9	0	0.0	0	0.0
OCT-2023	1198	273	22.8	893	74.5	35	2.9	0	0.0	0	0.0
NOV-2023	1184	260	22.0	890	75.2	35	3.0	0	0.0	0	0.0
DEC-2023	1156	248	21.5	876	75.8	33	2.9	0	0.0	0	0.0
JAN-2024	1138	241	21.2	866	76.1	33	2.9	0	0.0	0	0.0
FEB-2024	1111	229	20.6	852	76.7	31	2.8	0	0.0	0	0.0
MAR-2024	1094	225	20.6	840	76.8	30	2.7	0	0.0	0	0.0
APR-2024	1088	224	20.6	835	76.8	31	2.9	0	0.0	0	0.0
MAY-2024	1081	221	20.4	828	76.6	33	3.1	0	0.0	0	0.0
JUN-2024	1059	214	20.2	813	76.8	33	3.1	0	0.0	0	0.0
JUL-2024	1052	216	20.5	805	76.5	33	3.1	0	0.0	0	0.0
AUG-2024	1021	208	20.4	784	76.8	31	3.0	0	0.0	0	0.0
SEP-2024	1001	203	20.3	772	77.1	27	2.7	0	0.0	0	0.0
OCT-2024	977	197	20.2	754	77.2	27	2.8	0	0.0	0	0.0
NOV-2024	957	190	19.9	742	77.5	28	2.9	0	0.0	0	0.0
DEC-2024	947	184	19.4	738	77.9	26	2.8	0	0.0	0	0.0
JAN-2025	922	177	19.2	726	78.7	23	2.5	0	0.0	0	0.0
FEB-2025	891	168	18.9	700	78.6	24	2.7	0	0.0	0	0.0
MAR-2025	875	167	19.1	686	78.4	24	2.7	0	0.0	0	0.0
APR-2025	860	153	17.8	684	79.5	24	2.8	0	0.0	0	0.0
MAY-2025	840	151	18.0	666	79.3	24	2.9	0	0.0	0	0.0
JUN-2025	823	150	18.2	652	79.2	23	2.8	0	0.0	0	0.0

n is defined as number of participants on antiretroviral treatment which contains the INGREDIENT;  
 % is calculated as ratio of "n" and number of participants whose treatment is of the given antiretroviral drug class  
 Ritonavir - greater than 400 mg total daily dose

1.8 Distribution of Participants on Non-Nucleoside Analogue Reverse Transcriptase Inhibitors by INGREDIENT  
June 2020 - June 2025




**1.9 Number of Participants on Non-Nucleoside Analogue Reverse Transcriptase Inhibitors by INGREDIENT**

MON-YYYY	Total Participants	doravirine n %	efavirenz n %	etravirine n %	nevirapine n %	rilpivirine n %
JUL-2023	953	235 24.7	222 23.3	94 9.9	225 23.6	178 18.7
AUG-2023	951	238 25.0	222 23.3	91 9.6	223 23.5	182 19.1
SEP-2023	938	236 25.2	218 23.2	88 9.4	220 23.5	177 18.9
OCT-2023	932	238 25.5	216 23.2	89 9.6	220 23.6	173 18.6
NOV-2023	928	242 26.1	209 22.5	88 9.5	219 23.6	173 18.6
DEC-2023	929	250 26.9	205 22.1	87 9.4	213 22.9	176 19.0
JAN-2024	921	250 27.1	200 21.7	83 9.0	208 22.6	181 19.7
FEB-2024	919	257 28.0	192 20.9	82 8.9	207 22.5	182 19.8
MAR-2024	914	260 28.5	190 20.8	80 8.8	205 22.4	181 19.8
APR-2024	915	261 28.5	190 20.8	82 9.0	203 22.2	180 19.7
MAY-2024	906	262 28.9	186 20.5	80 8.8	205 22.6	175 19.3
JUN-2024	893	262 29.3	182 20.4	79 8.9	198 22.2	172 19.3
JUL-2024	890	270 30.3	176 19.8	78 8.8	194 21.8	172 19.3
AUG-2024	879	272 30.9	174 19.8	78 8.9	187 21.3	171 19.5
SEP-2024	886	275 31.0	172 19.4	76 8.6	185 20.9	179 20.2
OCT-2024	871	283 32.5	168 19.3	72 8.3	177 20.3	175 20.1
NOV-2024	850	287 33.8	162 19.1	70 8.2	159 18.7	173 20.4
DEC-2024	844	303 35.9	156 18.5	71 8.4	149 17.7	167 19.8
JAN-2025	844	309 36.6	157 18.6	67 7.9	143 16.9	172 20.4
FEB-2025	834	306 36.7	156 18.7	64 7.7	136 16.3	173 20.7
MAR-2025	823	311 37.8	147 17.9	62 7.5	132 16.0	173 21.0
APR-2025	818	317 38.8	137 16.8	61 7.5	128 15.7	177 21.6
MAY-2025	809	313 38.7	129 16.0	60 7.4	126 15.6	181 22.4
JUN-2025	812	315 38.8	127 15.6	60 7.4	122 15.0	190 23.4

**n** is defined as number of participants on antiretroviral treatment which contains the INGREDIENT;  
**%** is calculated as ratio of "n" and number of participants whose treatment is of the given antiretroviral drug class

1.10 Distribution of Participants on Integrase Inhibitors by INGREDIENT  
June 2020 - June 2025




**1.11 Number of Participants on Integrase Inhibitors by INGREDIENT**

MON-YYYY	Total Participants	bictegravir n %	cabotegravir n %	dolutegravir n %	elvitegravir n %	raltegravir n %
JUL-2023	<b>6201</b>	3218 51.9	5 0.1	2499 40.3	247 4.0	256 4.1
AUG-2023	<b>6240</b>	3258 52.2	7 0.1	2495 40.0	245 3.9	253 4.1
SEP-2023	<b>6263</b>	3289 52.5	8 0.1	2500 39.9	238 3.8	249 4.0
OCT-2023	<b>6294</b>	3298 52.4	7 0.1	2523 40.1	241 3.8	248 3.9
NOV-2023	<b>6311</b>	3327 52.7	9 0.1	2518 39.9	233 3.7	244 3.9
DEC-2023	<b>6330</b>	3365 53.2	13 0.2	2506 39.6	226 3.6	237 3.7
JAN-2024	<b>6389</b>	3418 53.5	16 0.3	2520 39.4	224 3.5	234 3.7
FEB-2024	<b>6417</b>	3453 53.8	15 0.2	2516 39.2	219 3.4	231 3.6
MAR-2024	<b>6435</b>	3498 54.4	17 0.3	2500 38.9	220 3.4	225 3.5
APR-2024	<b>6483</b>	3545 54.7	17 0.3	2497 38.5	216 3.3	225 3.5
MAY-2024	<b>6511</b>	3586 55.1	19 0.3	2488 38.2	213 3.3	222 3.4
JUN-2024	<b>6528</b>	3614 55.4	21 0.3	2488 38.1	207 3.2	218 3.3
JUL-2024	<b>6584</b>	3650 55.4	25 0.4	2500 38.0	212 3.2	213 3.2
AUG-2024	<b>6593</b>	3683 55.9	26 0.4	2487 37.7	204 3.1	207 3.1
SEP-2024	<b>6610</b>	3700 56.0	32 0.5	2495 37.8	200 3.0	205 3.1
OCT-2024	<b>6680</b>	3757 56.2	34 0.5	2508 37.5	198 3.0	199 3.0
NOV-2024	<b>6681</b>	3791 56.7	33 0.5	2487 37.2	191 2.9	193 2.9
DEC-2024	<b>6720</b>	3819 56.8	33 0.5	2521 37.5	185 2.8	187 2.8
JAN-2025	<b>6762</b>	3866 57.2	36 0.5	2525 37.3	185 2.7	179 2.7
FEB-2025	<b>6754</b>	3883 57.5	41 0.6	2495 36.9	183 2.7	176 2.6
MAR-2025	<b>6767</b>	3913 57.8	48 0.7	2481 36.7	181 2.7	175 2.6
APR-2025	<b>6834</b>	3985 58.3	49 0.7	2488 36.4	176 2.6	167 2.4
MAY-2025	<b>6840</b>	3987 58.3	57 0.8	2478 36.2	174 2.5	165 2.4
JUN-2025	<b>6868</b>	4021 58.6	67 1.0	2483 36.2	170 2.5	162 2.4

**n** is defined as number of participants on antiretroviral treatment which contains the INGREDIENT;  
**%** is calculated as ratio of "n" and number of participants whose treatment is of the given antiretroviral drug class



1.12 Distribution of Participants on Other Antiretroviral Drug Classes by INGREDIENT  
June 2020 - June 2025






1.13 Number of Participants on Other Antiretroviral Drug Classes by INGREDIENT

MON-YYYY	Total Participants	fostemsavir		maraviroc		lenacapavir	
		n	%	n	%	n	%
JUL-2023	20	2	10.0	18	90.0	0	0.0
AUG-2023	20	2	10.0	18	90.0	0	0.0
SEP-2023	20	2	10.0	18	90.0	0	0.0
OCT-2023	20	2	10.0	18	90.0	1	5.0
NOV-2023	19	1	5.3	17	89.5	1	5.3
DEC-2023	19	2	10.5	16	84.2	1	5.3
JAN-2024	21	2	9.5	18	85.7	1	4.8
FEB-2024	21	2	9.5	18	85.7	1	4.8
MAR-2024	21	3	14.3	17	81.0	2	9.5
APR-2024	22	2	9.1	18	81.8	2	9.1
MAY-2024	19	2	10.5	15	79.0	2	10.5
JUN-2024	21	2	9.5	17	81.0	2	9.5
JUL-2024	21	2	9.5	17	81.0	2	9.5
AUG-2024	21	2	9.5	17	81.0	2	9.5
SEP-2024	20	2	10.0	16	80.0	2	10.0
OCT-2024	20	2	10.0	15	75.0	3	15.0
NOV-2024	20	2	10.0	16	80.0	2	10.0
DEC-2024	20	2	10.0	16	80.0	2	10.0
JAN-2025	20	2	10.0	16	80.0	2	10.0
FEB-2025	19	2	10.5	15	79.0	2	10.5
MAR-2025	19	2	10.5	15	79.0	2	10.5
APR-2025	19	2	10.5	15	79.0	2	10.5
MAY-2025	17	2	11.8	14	82.4	1	5.9
JUN-2025	19	2	10.5	15	79.0	2	10.5

n is defined as number of participants on antiretroviral treatment which contains the INGREDIENT;  
 % is calculated as ratio of "n" and number of participants whose treatment is of the given antiretroviral drug class  
 Both lenacapavir and fostemsavir are currently not on BC-CfE Formulary



1.14 Distribution of Participants on Antiretroviral Treatment by Number of Antiretrovirals  
June 2020 - June 2025




**1.15 Distribution of Participants on Antiretroviral Treatment by Number of Antiretrovirals**

MON-YYYY	Total Participants	1 drug		2 drugs		3 drugs		4 drugs		5 or more drugs	
		n	%	n	%	n	%	n	%	n	%
JUL-2023	<b>7577</b>	2	0.0	842	11.1	6253	82.5	440	5.8	40	0.5
AUG-2023	<b>7600</b>	2	0.0	864	11.4	6240	82.1	448	5.9	46	0.6
SEP-2023	<b>7609</b>	2	0.0	879	11.6	6250	82.1	432	5.7	46	0.6
OCT-2023	<b>7610</b>	2	0.0	897	11.8	6237	82.0	433	5.7	41	0.5
NOV-2023	<b>7612</b>	2	0.0	918	12.1	6210	81.6	441	5.8	41	0.5
DEC-2023	<b>7603</b>	2	0.0	936	12.3	6191	81.4	434	5.7	40	0.5
JAN-2024	<b>7642</b>	2	0.0	952	12.5	6214	81.3	432	5.7	42	0.6
FEB-2024	<b>7647</b>	3	0.0	971	12.7	6198	81.1	436	5.7	39	0.5
MAR-2024	<b>7636</b>	2	0.0	991	13.0	6159	80.7	440	5.8	44	0.6
APR-2024	<b>7670</b>	2	0.0	1001	13.1	6184	80.6	437	5.7	46	0.6
MAY-2024	<b>7687</b>	2	0.0	1024	13.3	6188	80.5	434	5.7	39	0.5
JUN-2024	<b>7687</b>	1	0.0	1034	13.5	6181	80.4	429	5.6	42	0.6
JUL-2024	<b>7718</b>	2	0.0	1061	13.8	6184	80.1	434	5.6	37	0.5
AUG-2024	<b>7709</b>	2	0.0	1082	14.0	6155	79.8	431	5.6	39	0.5
SEP-2024	<b>7697</b>	2	0.0	1125	14.6	6101	79.3	426	5.5	43	0.6
OCT-2024	<b>7725</b>	1	0.0	1169	15.1	6087	78.8	427	5.5	41	0.5
NOV-2024	<b>7703</b>	1	0.0	1177	15.3	6069	78.8	417	5.4	39	0.5
DEC-2024	<b>7720</b>	2	0.0	1200	15.5	6054	78.4	424	5.5	40	0.5
JAN-2025	<b>7739</b>	2	0.0	1235	16.0	6047	78.1	416	5.4	39	0.5
FEB-2025	<b>7696</b>	2	0.0	1265	16.4	5977	77.7	414	5.4	38	0.5
MAR-2025	<b>7689</b>	4	0.1	1292	16.8	5942	77.3	414	5.4	37	0.5
APR-2025	<b>7719</b>	3	0.0	1321	17.1	5939	76.9	419	5.4	37	0.5
MAY-2025	<b>7705</b>	4	0.1	1370	17.8	5882	76.3	410	5.3	39	0.5
JUN-2025	<b>7713</b>	4	0.1	1428	18.5	5845	75.8	396	5.1	40	0.5

**n** is the number of individual drugs in antiretroviral treatment regimen (excluding low dose ritonavir and cobicistat used for pharmacokinetic boosting)



1.16 Percent Distribution of Active Participants by CD4 Count  
June 2020 - June 2025





1.17 Distribution of Active Participants by CD4 Count

Month	# of Pts with CD4: Unreported	# of Pts with CD4: < 200	# of Pts with CD4: 200 - 349	# of Pts with CD4: 350 - 500	# of Pts with CD4: > 500
JUL-2023	1233	239	578	927	3805
AUG-2023	1277	254	560	943	3767
SEP-2023	1330	243	547	951	3744
OCT-2023	1380	242	543	943	3727
NOV-2023	1416	237	542	937	3689
DEC-2023	1459	237	530	917	3703
JAN-2024	1496	238	529	916	3679
FEB-2024	1535	242	503	911	3673
MAR-2024	1567	255	498	924	3649
APR-2024	1612	253	486	944	3627
MAY-2024	1647	248	486	923	3661
JUN-2024	1686	247	493	886	3679
JUL-2024	1748	248	493	912	3681
AUG-2024	1793	251	491	910	3659
SEP-2024	1812	241	489	935	3638
OCT-2024	1847	243	499	948	3624
NOV-2024	1882	234	505	917	3652
DEC-2024	1911	232	508	928	3658
JAN-2025	1940	233	509	939	3650
FEB-2025	1959	223	511	930	3640
MAR-2025	1981	225	508	934	3620
APR-2025	2022	230	500	903	3666
MAY-2025	2048	229	492	876	3652
JUN-2025	2096	224	476	900	3652


CD4 value (cells/μL) as per the most recent test within the past 12 months

CD4 Unreported: CD4 not tested or reported within the past 12 months

Active Participants are participants with antiretroviral treatment in the month based on dispensing record



1.18 Initial Regimen Composition for Antiretroviral Treatment Naïve Participants Starting Treatment  
June 2020 - June 2025




**1.19 Initial Regimen Composition for Antiretroviral Treatment Naïve Participants Starting Treatment**

MON-YYYY	Total	INSTI		Boosted PI		NNRTI		2 drugs from 2 classes		≥3 drugs from ≥3 classes		Other	
		n	%	n	%	n	%	n	%	n	%	n	%
JUL-2023	11	8	72.7	0	0.0	0	0.0	0	0.0	3	27.3	0	0.0
AUG-2023	13	12	92.3	0	0.0	0	0.0	0	0.0	1	7.7	0	0.0
SEP-2023	5	5	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
OCT-2023	10	9	90.0	0	0.0	0	0.0	1	10.0	0	0.0	0	0.0
NOV-2023	9	7	77.8	0	0.0	0	0.0	1	11.1	1	11.1	0	0.0
DEC-2023	13	12	92.3	0	0.0	0	0.0	0	0.0	1	7.7	0	0.0
JAN-2024	11	9	81.8	0	0.0	0	0.0	0	0.0	2	18.2	0	0.0
FEB-2024	11	11	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
MAR-2024	13	12	92.3	0	0.0	0	0.0	0	0.0	1	7.7	0	0.0
APR-2024	20	18	90.0	0	0.0	0	0.0	0	0.0	2	10.0	0	0.0
MAY-2024	16	16	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
JUN-2024	23	22	95.7	0	0.0	0	0.0	0	0.0	1	4.3	0	0.0
JUL-2024	10	10	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
AUG-2024	15	15	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
SEP-2024	7	7	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
OCT-2024	15	15	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
NOV-2024	9	8	88.9	0	0.0	1	11.1	0	0.0	0	0.0	0	0.0
DEC-2024	10	10	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
JAN-2025	14	14	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
FEB-2025	9	9	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
MAR-2025	12	12	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
APR-2025	12	12	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
MAY-2025	17	17	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
JUN-2025	8	8	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0

**INSTI:** Integrase Inhibitor, **PI:** Protease Inhibitor, **NNRTI:** Non-Nucleoside Analogue Reverse Transcriptase Inhibitor, **N(t)RTI:** Nucleos(t)ide Analogue Reverse Transcriptase Inhibitor  
**n** is number of participants on the specified regimen category in the specified month  
**%** is ratio of n and total number of participants initiating antiretroviral treatment in the specified month



1.20 Pre-entry CD4 for Antiretroviral Treatment Naïve Participants in the HIV Treatment Program  
June 2020 - June 2025




**1.21 Pre-entry CD4 for Antiretroviral Treatment Naive Participants in the HIV Treatment Program**

MON-YYYY	# of First Starts	# of Pts with CD4: Unreported		# of Pts with CD4: < 200		# of Pts with CD4: 200 - 349		# of Pts with CD4: 350 - 500		# of Pts with CD4: > 500	
		n	%	n	%	n	%	n	%	n	%
JUL-2023	11	0	0.0	3	27.3	3	27.3	2	18.2	3	27.3
AUG-2023	13	2	15.4	3	23.1	4	30.8	2	15.4	2	15.4
SEP-2023	5	0	0.0	2	40.0	0	0.0	0	0.0	3	60.0
OCT-2023	10	1	10.0	1	10.0	3	30.0	2	20.0	3	30.0
NOV-2023	9	1	11.1	2	22.2	0	0.0	2	22.2	4	44.4
DEC-2023	13	1	7.7	1	7.7	3	23.1	0	0.0	8	61.5
JAN-2024	11	1	9.1	4	36.4	2	18.2	1	9.1	3	27.3
FEB-2024	11	1	9.1	3	27.3	4	36.4	2	18.2	1	9.1
MAR-2024	13	2	15.4	5	38.5	1	7.7	1	7.7	4	30.8
APR-2024	20	0	0.0	4	20.0	6	30.0	1	5.0	9	45.0
MAY-2024	16	1	6.3	5	31.3	3	18.8	1	6.3	6	37.5
JUN-2024	23	0	0.0	2	8.7	10	43.5	4	17.4	7	30.4
JUL-2024	10	1	10.0	1	10.0	3	30.0	3	30.0	2	20.0
AUG-2024	15	0	0.0	5	33.3	4	26.7	3	20.0	3	20.0
SEP-2024	7	0	0.0	1	14.3	4	57.1	1	14.3	1	14.3
OCT-2024	15	0	0.0	6	40.0	3	20.0	3	20.0	3	20.0
NOV-2024	9	0	0.0	3	33.3	3	33.3	2	22.2	1	11.1
DEC-2024	10	0	0.0	4	40.0	2	20.0	2	20.0	2	20.0
JAN-2025	14	0	0.0	6	42.9	2	14.3	5	35.7	1	7.1
FEB-2025	9	0	0.0	2	22.2	1	11.1	3	33.3	3	33.3
MAR-2025	12	1	8.3	5	41.7	2	16.7	2	16.7	2	16.7
APR-2025	12	1	8.3	3	25.0	2	16.7	2	16.7	4	33.3
MAY-2025	17	1	5.9	6	35.3	3	17.7	5	29.4	2	11.8
JUN-2025	8	0	0.0	2	25.0	3	37.5	2	25.0	1	12.5

**First Starts** defined as participants starting antiretroviral treatment in the specified month for the first time (antiretroviral treatment naive)  
**Pre-entry CD4** (cells/ $\mu$ L) is defined as most recent CD4 test before antiretroviral treatment start

1.22 Antiretroviral Resistance by Drug Class Among Participants on Antiretroviral Treatment  
June 2020 - June 2025





**1.23 Antiretroviral Resistance by Drug Class Among Participants on Antiretroviral Treatment**

MON-YYYY	On Antiretroviral (ARV) Treatment	Ever Tested	NNRTI		N(t)RTI		PI		INSTI	
			n	%	n	%	n	%	n	%
JUL-2023	7555	6421	1313	20.5	1679	26.2	563	8.8	106	1.7
AUG-2023	7577	6421	1313	20.5	1664	25.9	557	8.7	107	1.7
SEP-2023	7579	6406	1304	20.4	1645	25.7	557	8.7	104	1.6
OCT-2023	7579	6394	1307	20.4	1648	25.8	552	8.6	99	1.6
NOV-2023	7578	6388	1307	20.5	1644	25.7	558	8.7	101	1.6
DEC-2023	7574	6374	1306	20.5	1634	25.6	553	8.7	100	1.6
JAN-2024	7613	6399	1306	20.4	1645	25.7	549	8.6	102	1.6
FEB-2024	7620	6409	1301	20.3	1647	25.7	562	8.8	102	1.6
MAR-2024	7616	6393	1294	20.2	1638	25.6	555	8.7	105	1.6
APR-2024	7647	6411	1299	20.3	1637	25.5	563	8.8	102	1.6
MAY-2024	7666	6419	1301	20.3	1637	25.5	566	8.8	103	1.6
JUN-2024	7678	6419	1306	20.4	1626	25.3	560	8.7	101	1.6
JUL-2024	7697	6425	1315	20.5	1636	25.5	557	8.7	107	1.7
AUG-2024	7686	6410	1304	20.3	1620	25.3	547	8.5	105	1.6
SEP-2024	7674	6391	1299	20.3	1622	25.4	553	8.7	102	1.6
OCT-2024	7702	6408	1285	20.1	1618	25.3	555	8.7	99	1.5
NOV-2024	7674	6374	1279	20.1	1614	25.3	544	8.5	97	1.5
DEC-2024	7693	6373	1279	20.1	1601	25.1	541	8.5	101	1.6
JAN-2025	7712	6374	1272	20.0	1588	24.9	529	8.3	105	1.7
FEB-2025	7673	6328	1268	20.0	1575	24.9	530	8.4	106	1.7
MAR-2025	7668	6327	1259	19.9	1561	24.7	531	8.4	108	1.7
APR-2025	7702	6345	1263	19.9	1569	24.7	524	8.3	104	1.6
MAY-2025	7676	6322	1265	20.0	1561	24.7	529	8.4	104	1.7
JUN-2025	7692	6321	1262	20.0	1554	24.6	521	8.2	104	1.7

**On Antiretroviral (ARV) Treatment:** based on dispensing data, participants with a record of ARV medication in the specified month and not deceased or moved out of program.

**Ever Tested:** those on ARV treatment, with at least one ARV resistance test on record in BC, up until the month of interest.

**n:** number of participants on ARV treatment who were ever tested for ARV resistance with drug resistance to ≥1 drug in the corresponding drug class in BC. Participants may have resistance to none or 1 or more drug class(es).

**%** is calculated as ratio of "n" and number of participants on ARV treatment who were ever tested for ARV resistance with drug resistance to ≥1 drug the corresponding drug class in BC.

Resistance interpretations are performed using the Stanford University HIV Drug Resistance Database Algorithm (HIVdb) version 9.8.


HIVdb scores ≥15 are classified as "resistant".

**INSTI:** Integrase Inhibitor, **PI:** Protease Inhibitor, **NNRTI:** Non-Nucleoside Analogue Reverse Transcriptase Inhibitor,

**N(t)RTI:** Nucleos(t)ide Analogue Reverse Transcriptase Inhibitor



1.24 Active Participants by number of Antiretroviral Drug Classes with Resistance  
June 2020 - June 2025



**1.25 Active Participants by number of Antiretroviral Drug Classes with Resistance**

MON-YYYY	On Antiretroviral Treatment	Ever Tested	0-Class (Wild Type)		1-Class		2-Class		3 or more Class	
			n	%	n	%	n	%	n	%
JUL-2023	7555	6421	4087	63.7	1290	20.1	765	11.9	279	4.4
AUG-2023	7577	6421	4097	63.8	1287	20.0	761	11.9	276	4.3
SEP-2023	7579	6406	4098	64.0	1281	20.0	755	11.8	272	4.3
OCT-2023	7579	6394	4086	63.9	1282	20.1	758	11.9	268	4.2
NOV-2023	7578	6388	4076	63.8	1288	20.2	754	11.8	270	4.2
DEC-2023	7574	6374	4070	63.9	1287	20.2	749	11.8	268	4.2
JAN-2024	7613	6399	4087	63.9	1293	20.2	751	11.7	268	4.2
FEB-2024	7620	6409	4098	63.9	1285	20.1	755	11.8	271	4.2
MAR-2024	7616	6393	4096	64.1	1277	20.0	749	11.7	271	4.2
APR-2024	7647	6411	4103	64.0	1292	20.2	743	11.6	273	4.3
MAY-2024	7666	6419	4107	64.0	1292	20.1	749	11.7	271	4.2
JUN-2024	7678	6419	4117	64.1	1286	20.0	743	11.6	273	4.3
JUL-2024	7697	6425	4110	64.0	1294	20.1	746	11.6	275	4.3
AUG-2024	7686	6410	4115	64.2	1288	20.1	737	11.5	270	4.2
SEP-2024	7674	6391	4098	64.1	1286	20.1	735	11.5	272	4.3
OCT-2024	7702	6408	4120	64.3	1288	20.1	734	11.5	266	4.2
NOV-2024	7674	6374	4098	64.3	1282	20.1	732	11.5	262	4.1
DEC-2024	7693	6373	4104	64.4	1277	20.0	733	11.5	259	4.1
JAN-2025	7712	6374	4115	64.6	1277	20.0	731	11.5	251	3.9
FEB-2025	7673	6328	4078	64.4	1274	20.1	724	11.4	252	4.0
MAR-2025	7668	6327	4086	64.6	1276	20.2	715	11.3	250	4.0
APR-2025	7702	6345	4104	64.7	1274	20.1	718	11.3	249	3.9
MAY-2025	7676	6322	4082	64.6	1273	20.1	718	11.4	249	3.9
JUN-2025	7692	6321	4091	64.7	1268	20.1	716	11.3	246	3.9

**Number of Antiretroviral (ARV) Drug Classes with Resistance** considers N(t)RTIs, NNRTIs, PIs, and INSTIs only, based on cumulative resistance tests performed in BC (until the specified month) for participants ever tested (see definition below).

Resistance interpretations are performed using the Stanford University HIV Drug Resistance Database Algorithm (HIVdb) version 9.8.

HIVdb scores  $\geq 15$  are classified as "resistant".

**On Antiretroviral Treatment:** based on dispensing data, participants with a record of ARV medication in the specified month and not deceased or moved out of program.

**Ever tested:** those on ARV treatment, with at least one ARV resistance test on record in BC, up until the specified month.





2.1 Active participants by Year of Program Initiation (1987 - 2025) - as of June 2025

DTP Start Year	Duration (years) Median	First Starts	All	Male	Female	Age		(n)	CD4 (cells/ $\mu$ L)		(n)	pVL (copies/mL)	
						Median	(Q1, Q3)		Median	(Q1, Q3)		Median	(Q1, Q3)
Pre-1993	31	48	182	173	9	34	(30, 39)	89	560	(400, 770)	168	<40	(<40, <40)
1993	30	121	122	108	14	34	(29, 39)	74	605	(420, 810)	115	<40	(<40, <40)
1994	29	67	67	58	9	35	(30, 38)	44	665	(440, 843)	62	<40	(<40, <40)
1995	28	123	124	105	19	34	(29, 39)	73	620	(430, 780)	112	<40	(<40, <40)
1996	26	320	322	279	43	35	(30, 39)	184	620	(438, 820)	295	<40	(<40, <40)
1997	24	262	267	242	25	34	(30, 39)	159	620	(400, 865)	237	<40	(<40, <40)
1998	24	183	192	161	31	34	(30, 40)	127	610	(420, 795)	176	<40	(<40, <40)
1999	24	166	167	130	37	36	(31, 42)	112	595	(395, 830)	156	<40	(<40, <40)
2000	24	113	116	94	22	38	(33, 43)	69	640	(440, 780)	104	<40	(<40, <40)
2001	23	116	118	93	25	37	(30, 44)	75	630	(390, 805)	106	<40	(<40, <40)
2002	22	114	123	105	18	39	(30, 46)	73	540	(440, 740)	111	<40	(<40, <40)
2003	22	141	151	128	23	39	(34, 46)	96	580	(435, 773)	129	<40	(<40, <40)
2004	21	144	165	129	36	40	(35, 44)	111	570	(385, 780)	156	<40	(<40, <40)
2005	20	182	199	159	40	40	(35, 47)	141	660	(450, 860)	180	<40	(<40, <40)
2006	19	178	197	159	38	41	(33, 48)	134	603	(443, 790)	179	<40	(<40, <40)
2007	18	232	251	217	34	41	(35, 46)	171	670	(475, 865)	229	<40	(<40, <40)
2008	17	274	308	250	58	42	(34, 48)	225	680	(500, 900)	272	<40	(<40, <40)
2009	16	290	323	267	56	41	(35, 47)	213	670	(460, 920)	283	<40	(<40, <40)
2010	15	262	301	238	63	40	(32, 45)	214	660	(500, 860)	266	<40	(<40, <40)
2011	14	317	360	295	65	41	(33, 48)	230	735	(503, 918)	314	<40	(<40, <40)
2012	13	276	314	253	61	40	(32, 49)	194	750	(550, 988)	284	<40	(<40, <40)
2013	12	245	294	236	58	40	(32, 49)	195	710	(480, 905)	250	<40	(<40, <40)
2014	11	223	294	251	43	40	(31, 50)	187	740	(530, 980)	251	<40	(<40, <40)
2015	10	196	278	237	41	41	(31, 51)	185	680	(500, 910)	248	<40	(<40, <40)
2016	9	179	253	209	44	38	(32, 49)	167	670	(500, 920)	212	<40	(<40, <40)
2017	8	155	222	188	34	36	(28, 45)	158	675	(510, 930)	210	<40	(<40, <40)
2018	7	135	208	165	43	39	(31, 48)	135	800	(544, 990)	177	<40	(<40, <40)
2019	6	135	250	209	41	38	(29, 48)	190	730	(520, 900)	213	<40	(<40, <40)
2020	5	105	205	155	50	37	(30, 48)	154	740	(523, 930)	177	<40	(<40, <40)

Duration defined as cumulative years on antiretroviral treatment, excluding periods of treatment interruption  
 CD4 and pVL tests defined as most recent test done in the last 12 months and last 6 months, respectively





2.1 Active participants by Year of Program Initiation (1987 - 2025) - as of June 2025 (cont.)

DTP Start Year	Duration (years) Median	First Starts	All	Male	Female	Age		(n)	CD4 (cells/ $\mu$ L)		(n)	pVL (copies/mL)	
						Median	(Q1, Q3)		Median	(Q1, Q3)		Median	(Q1, Q3)
2021	4	112	202	171	31	37	(30, 46)	179	645	(440, 873)	142	<40	(<40, <40)
2022	3	110	272	224	48	38	(31, 47)	250	690	(523, 908)	206	<40	(<40, <40)
2023	2	112	315	257	58	35	(30, 45)	291	630	(450, 820)	247	<40	(<40, <40)
2024	1	134	356	285	71	36	(29, 45)	331	600	(438, 823)	312	<40	(<40, <40)
2025	0	69	174	127	47	36	(30, 45)	172	565	(351, 750)	166	<40	(<40, 49)
<b>Total:</b>		<b>5839</b>	<b>7692</b>	<b>6357</b>	<b>1335</b>								

**Duration** defined as cumulative years on antiretroviral treatment, excluding periods of treatment interruption  
**CD4 and pVL tests** defined as most recent test done in the last 12 months and last 6 months, respectively





**2.2 HIV Viral Load (copies/mL) and CD4 (cells/ $\mu$ L) for Participants on Antiretroviral Treatment**

MON-YYYY	Total Participants	Median # of Treatment days	(n)	CD4 (cells/ $\mu$ L)		(n)	pVL (copies/mL)	
				Median	(Q1, Q3)		Median	(Q1, Q3)
JUL-2023	7577	805	5549	650	(450, 860)	6938	<40	(<40, <40)
AUG-2023	7600	804	5524	641	(450, 860)	6890	<40	(<40, <40)
SEP-2023	7609	796	5485	650	(450, 860)	6893	<40	(<40, <40)
OCT-2023	7610	803	5455	640	(450, 860)	6812	<40	(<40, <40)
NOV-2023	7612	795	5405	640	(450, 860)	6841	<40	(<40, <40)
DEC-2023	7603	798	5387	650	(460, 860)	6829	<40	(<40, <40)
JAN-2024	7642	792	5362	640	(460, 860)	6815	<40	(<40, <40)
FEB-2024	7647	781	5329	650	(460, 870)	6865	<40	(<40, <40)
MAR-2024	7636	790	5326	640	(450, 870)	6872	<40	(<40, <40)
APR-2024	7670	786	5310	640	(450, 870)	6843	<40	(<40, <40)
MAY-2024	7687	787	5318	650	(460, 880)	6897	<40	(<40, <40)
JUN-2024	7687	784	5305	650	(460, 870)	6922	<40	(<40, <40)
JUL-2024	7718	786	5334	650	(460, 870)	7010	<40	(<40, <40)
AUG-2024	7709	782	5311	650	(460, 870)	6938	<40	(<40, <40)
SEP-2024	7697	791	5303	650	(460, 870)	6905	<40	(<40, <40)
OCT-2024	7725	787	5314	650	(460, 870)	6899	<40	(<40, <40)
NOV-2024	7703	793	5308	650	(460, 880)	6876	<40	(<40, <40)
DEC-2024	7720	796	5326	650	(460, 880)	6914	<40	(<40, <40)
JAN-2025	7739	792	5331	650	(450, 880)	6883	<40	(<40, <40)
FEB-2025	7696	800	5304	650	(460, 880)	6871	<40	(<40, <40)
MAR-2025	7689	792	5287	650	(450, 875)	6813	<40	(<40, <40)
APR-2025	7719	779	5299	660	(460, 880)	6891	<40	(<40, <40)
MAY-2025	7705	787	5249	660	(460, 880)	6861	<40	(<40, <40)
JUN-2025	7713	785	5252	660	(460, 880)	6835	<40	(<40, <40)

**Active participant** defined as being on antiretroviral treatment in the specified month

**Treatment days** defined as number of consecutive days on antiretroviral treatment (most recent uninterrupted period)

**CD4 and pVL tests** defined as tests done in the specified month





2.3 BC-CfE HIV Treatment Program Enrolment

MON-YYYY	On ARV Treatment	Off ARV Treatment	Deceased	ARV Treatment naïve starts	ARV Treatment experienced starts	Newly interrupted ARV Treatment	Net Change
JUL-2023	7555	728	11	11	164	181	-22
AUG-2023	7577	727	11	13	217	192	22
SEP-2023	7579	714	14	5	179	163	2
OCT-2023	7579	724	18	10	170	160	0
NOV-2023	7578	731	18	9	182	171	-1
DEC-2023	7574	740	14	13	169	169	-4
JAN-2024	7613	698	16	11	204	159	39
FEB-2024	7620	695	17	11	184	165	7
MAR-2024	7616	709	12	13	183	185	-4
APR-2024	7647	692	17	20	197	168	31
MAY-2024	7666	691	12	16	191	173	19
JUN-2024	7678	706	5	23	173	177	12
JUL-2024	7697	695	15	10	185	159	19
AUG-2024	7686	710	13	15	164	168	-11
SEP-2024	7674	716	9	7	182	186	-12
OCT-2024	7702	709	8	15	200	172	28
NOV-2024	7674	746	14	9	181	199	-28
DEC-2024	7693	743	15	10	194	170	19
JAN-2025	7712	716	14	14	196	170	19
FEB-2025	7673	759	10	9	166	201	-39
MAR-2025	7668	759	12	12	175	177	-5
APR-2025	7702	736	9	12	192	157	34
MAY-2025	7676	757	18	17	167	188	-26
JUN-2025	7692	736	12	8	175	150	16

**ARV:** antiretroviral

**On ARV Treatment:** based on dispensing data, participants with a record of ARV medication in the specified month and not deceased or moved out of program

**Off ARV Treatment:** based on dispensing data, participants with no record of ARV medication in the specified month and not deceased or moved out of program

**Deceased:** in the specified month, and on ARV treatment in the previous month

**ARV Treatment naïve starts:** participants starting ARV treatment in the specified month for the first time


**ARV Treatment experienced starts:** participants with history of ARV treatment, but first dispensing in the BC HIV Treatment Program in the specified month

**Newly Interrupted ARV Treatment:** based on dispensing data, participants with no record of ARV medication in the specified month, but had a record of ARV medication in the previous month, and not deceased or moved out of program, and had contact with the program in the past 5 years.

**Net Change:** the difference between ARV treatment starts (naïve and experienced) and ARV treatment stops (Deceased, moved out of program, or newly interrupted ARV treatment)




3.1 Distribution of HIV Treatment Program Active Participants  
June 2025






3.2 Distribution of HIV Treatment Program Active Participants June 2025

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA




KELOWNA BY POSTAL CODE






3.3 Distribution of HIV Treatment Program Active Participants  
June 2025

FRASER HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA




SURREY BY POSTAL CODE




3.4 Distribution of HIV Treatment Program Active Participants  
June 2025

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE



\*\*\* Please refer to VIHA (432 and 434) on the next page







### 3.5 Distribution of HIV Treatment Program Active Participants June 2025



#### VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA

N = 1069



#### VICTORIA BY POSTAL CODE


N = 520






3.6 Distribution of HIV Treatment Program Active Participants June 2025

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants by Age & Sex at Birth INTERIOR Health Authority (HA)

Health Service Delivery Area	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
EAST KOOTENAY	0 - 29	*	*	0	0	N/A	*	*
	30 - 49	*	*	0	13	750	*	*
	50 - 64	*	*	0	13	740	*	*
	65+	*	*	0	6	590	*	*
	<b>Total HSDA:</b>	<b>36</b>	<b>32</b>	<b>0</b>	<b>32</b>	<b>750</b>	<b>29</b>	<b>&lt;40</b>
KOOTENAY BOUNDARY	0 - 29	5	5	0	5	880	*	*
	30 - 49	14	13	0	12	770	*	*
	50 - 64	21	18	0	17	540	*	*
	65+	18	18	0	13	740	*	*
	<b>Total HSDA:</b>	<b>58</b>	<b>54</b>	<b>0</b>	<b>47</b>	<b>750</b>	<b>45</b>	<b>&lt;40</b>
OKANAGAN	0 - 29	15	14	0	15	690	12	<40
	30 - 49	124	116	0	112	715	91	<40
	50 - 64	159	150	0	143	670	127	<40
	65+	84	82	0	78	570	73	<40
	<b>Total HSDA:</b>	<b>382</b>	<b>362</b>	<b>0</b>	<b>348</b>	<b>660</b>	<b>303</b>	<b>&lt;40</b>
THOMPSON/CARIBOO/SHUSWAP	0 - 29	14	12	0	11	680	10	<40
	30 - 49	55	46	0	44	755	40	<40
	50 - 64	86	79	0	70	680	67	<40
	65+	36	36	0	30	680	33	<40
	<b>Total HSDA:</b>	<b>191</b>	<b>173</b>	<b>0</b>	<b>155</b>	<b>680</b>	<b>150</b>	<b>&lt;40</b>
<b>Total HA:</b>		<b>667</b>	<b>621</b>	<b>0</b>	<b>582</b>	<b>680</b>	<b>527</b>	<b>&lt;40</b>

	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	0 - 29	35	32	0	31	690	25	<40
	30 - 49	207	186	0	181	740	155	<40
	50 - 64	280	261	0	243	680	220	<40
	65+	145	142	0	127	610	127	<40
<b>Total HA:</b>		<b>667</b>	<b>621</b>	<b>0</b>	<b>582</b>	<b>680</b>	<b>527</b>	<b>&lt;40</b>

Sex at Birth	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
Male	537	501	0	465	670	425	<40
Female	130	120	0	117	710	102	<40
Unknown	0	0	0	0	N/A	0	N/A

Currently on antiretroviral treatment	# of Participants	Median Age	Median CD4	Median pVL
<b>Total HA:</b>	<b>621</b>	<b>56</b>	<b>680</b>	<b>&lt;40</b>

\* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

# **Enrolled:** Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program  
 # **on ART:** # of participants on antiretroviral treatment (ART) in the specified month based on dispensing record  
 # **CD4 or pVL tested:** participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/μL and pVL in copies/mL)



**4.2 Distribution of Participants by Program Duration INTERIOR Health Authority**

HSDA	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
EAST KOOTENAY	10 years or more	17	14	0	16	710	12	<40
	5 years or more	11	11	0	7	880	9	<40
	<5 years	8	7	0	9	810	8	<40
	Never on ART	0	0	0	0	N/A	0	N/A
	<b>Total HSDA:</b>	<b>36</b>	<b>32</b>	<b>0</b>	<b>32</b>	<b>750</b>	<b>29</b>	<b>&lt;40</b>
KOOTENAY BOUNDARY	10 years or more	43	40	0	34	690	*	*
	5 years or more	7	6	0	5	780	*	*
	<5 years	8	8	0	8	765	*	*
	Never on ART	0	0	0	0	N/A	*	*
	<b>Total HSDA:</b>	<b>58</b>	<b>54</b>	<b>0</b>	<b>47</b>	<b>750</b>	<b>45</b>	<b>&lt;40</b>
OKANAGAN	10 years or more	243	235	0	219	670	189	<40
	5 years or more	60	56	0	54	715	48	<40
	<5 years	79	71	0	75	580	66	<40
	Never on ART	0	0	0	0	N/A	0	N/A
	<b>Total HSDA:</b>	<b>382</b>	<b>362</b>	<b>0</b>	<b>348</b>	<b>660</b>	<b>303</b>	<b>&lt;40</b>
THOMPSON/CARIBOO/SHUSWAP	10 years or more	121	110	0	101	700	94	<40
	5 years or more	24	19	0	15	810	16	<40
	<5 years	46	44	0	39	600	40	<40
	Never on ART	0	0	0	0	N/A	0	N/A
	<b>Total HSDA:</b>	<b>191</b>	<b>173</b>	<b>0</b>	<b>155</b>	<b>680</b>	<b>150</b>	<b>&lt;40</b>
<b>Total HA:</b>		<b>667</b>	<b>621</b>	<b>0</b>	<b>582</b>	<b>680</b>	<b>527</b>	<b>&lt;40</b>

	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	10 years or more	424	399	0	370	680	331	<40
	5 years or more	102	92	0	81	740	75	<40
	<5 years	141	130	0	131	630	121	<40
	Never on ART	0	0	0	0	N/A	0	N/A
<b>Total HA:</b>		<b>667</b>	<b>621</b>	<b>0</b>	<b>582</b>	<b>680</b>	<b>527</b>	<b>&lt;40</b>

\* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

# **Enrolled:** Participants who had enrolled in HIV Treatment Program, not known to be deceased or formally reported as moved out of program

# **on ART:** Participants on antiretroviral treatment (ART) in the specified month based on dispensing record (as above footnote)

**Program Duration:** years since first antiretroviral treatment dispensing in BC HIV Treatment Program

# **CD4 or pVL tested:** participants tested for CD4 or pVL within the past 12 months and 6 months, respectively





4.3 Distribution of Antiretroviral Treatment Prescribers INTERIOR Health Authority

HSDA of Prescriber Residency	# of Prescribers currently prescribing Antiretroviral Treatment	# of Participants currently treated by Prescribers	# of Prescribers ever prescribed Antiretroviral Treatment	# of Participants ever treated by Prescribers
EAST KOOTENAY	13	32	53	103
KOOTENAY BOUNDARY	20	40	78	141
OKANAGAN	52	335	245	1116
THOMPSON/CARIBOO/SHUSWAP	32	141	152	594
<b>Total:</b>	<b>117</b>	<b>548</b>	<b>528</b>	<b>1954</b>

HSDA of Participant Residency	# of Participants with Prescriber out of HA/HSDA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
<b>Total:</b>	<b>128</b>

\* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

**Currently prescribing Antiretroviral Treatment:** number of prescribers of antiretroviral treatment dispensed in the previous 6 months (based on participant HA/HSDA)

**Currently treated:** number of participants with antiretroviral treatment dispensed in the previous 6 months by antiretroviral treatment prescribers (based on follow-up prescriber HA/HSDA)

**Prescribers ever prescribed Antiretroviral Treatment:** for participants residing in HA/HSDA

**Participants ever treated by prescribers:** where follow-up prescriber is in the HA/HSDA

**Participants with Prescriber out of HA/HSDA:** participants residing in specified HA/HSDA with follow-up prescriber(s) in another HA/HSDA



**4.4 Distribution of Participants by Age & Sex at Birth FRASER Health Authority (HA)**

Health Service Delivery Area	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
FRASER EAST	0 - 29	27	23	*	29	760	26	<40
	30 - 49	114	98	*	83	697	91	<40
	50 - 64	158	141	*	104	600	131	<40
	65+	68	66	*	47	700	64	<40
	<b>Total HSDA:</b>	<b>367</b>	<b>328</b>	<b>&lt;5</b>	<b>263</b>	<b>660</b>	<b>312</b>	<b>&lt;40</b>
FRASER NORTH	0 - 29	50	47	*	45	600	47	<40
	30 - 49	380	334	*	303	720	315	<40
	50 - 64	357	337	*	236	670	314	<40
	65+	176	170	*	108	600	154	<40
	<b>Total HSDA:</b>	<b>963</b>	<b>888</b>	<b>&lt;5</b>	<b>692</b>	<b>680</b>	<b>830</b>	<b>&lt;40</b>
FRASER SOUTH	0 - 29	70	64	*	57	590	66	<40
	30 - 49	359	330	*	255	680	319	<40
	50 - 64	396	366	*	252	650	337	<40
	65+	165	161	*	119	549	154	<40
	<b>Total HSDA:</b>	<b>990</b>	<b>921</b>	<b>&lt;5</b>	<b>683</b>	<b>640</b>	<b>876</b>	<b>&lt;40</b>
<b>Total HA:</b>		<b>2320</b>	<b>2137</b>	<b>6</b>	<b>1638</b>	<b>660</b>	<b>2018</b>	<b>&lt;40</b>

	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	0 - 29	147	134	*	131	630	139	<40
	30 - 49	853	762	*	641	700	725	<40
	50 - 64	911	844	*	592	650	782	<40
	65+	409	397	*	274	585	372	<40
<b>Total HA:</b>		<b>2320</b>	<b>2137</b>	<b>6</b>	<b>1638</b>	<b>660</b>	<b>2018</b>	<b>&lt;40</b>

Sex at Birth	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
Male	1753	1627	*	1196	649	1544	<40
Female	567	510	*	442	702.5	474	<40
Unknown	0	0	*	0	N/A	0	N/A

Currently on antiretroviral treatment	# of Participants	Median Age	Median CD4	Median pVL
<b>Total HA:</b>	<b>2137</b>	<b>53</b>	<b>670</b>	<b>&lt;40</b>

\* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

# **Enrolled**: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program  
 # **on ART**: # of participants on antiretroviral treatment (ART) in the specified month based on dispensing record  
 # **CD4** or **pVL** tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ $\mu$ L and pVL in copies/mL)





4.5 Distribution of Participants by Program Duration FRASER Health Authority

HSDA	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
FRASER EAST	10 years or more	229	208	*	*	*	*	*
	5 years or more	59	44	*	*	*	*	*
	<5 years	79	76	*	*	*	*	*
	Never on ART	0	0	*	*	*	*	*
	<b>Total HSDA:</b>	<b>367</b>	<b>328</b>	<b>&lt;5</b>	<b>263</b>	<b>660</b>	<b>312</b>	<b>&lt;40</b>
FRASER NORTH	10 years or more	603	566	*	404	710	*	*
	5 years or more	160	138	*	120	725	*	*
	<5 years	200	184	*	168	625	*	*
	Never on ART	0	0	*	0	N/A	*	*
	<b>Total HSDA:</b>	<b>963</b>	<b>888</b>	<b>&lt;5</b>	<b>692</b>	<b>680</b>	<b>830</b>	<b>&lt;40</b>
FRASER SOUTH	10 years or more	573	526	*	379	650	493	<40
	5 years or more	167	151	*	104	640	140	<40
	<5 years	250	244	*	195	610	238	<40
	Never on ART	0	0	*	5	670	5	<40
	<b>Total HSDA:</b>	<b>990</b>	<b>921</b>	<b>&lt;5</b>	<b>683</b>	<b>640</b>	<b>876</b>	<b>&lt;40</b>
<b>Total HA:</b>		<b>2320</b>	<b>2137</b>	<b>6</b>	<b>1638</b>	<b>660</b>	<b>2018</b>	<b>&lt;40</b>

	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	10 years or more	1405	1300	0	942	670	1204	<40
	5 years or more	386	333	0	257	670	314	<40
	<5 years	529	504	6	433	620	493	<40
	Never on ART	0	0	0	6	628.5	7	<40
<b>Total HA:</b>		<b>2320</b>	<b>2137</b>	<b>6</b>	<b>1638</b>	<b>660</b>	<b>2018</b>	<b>&lt;40</b>

\* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

# **Enrolled:** Participants who had enrolled in HIV Treatment Program, not known to be deceased or formally reported as moved out of program

# **on ART:** Participants on antiretroviral treatment (ART) in the specified month based on dispensing record (as above footnote)

**Program Duration:** years since first antiretroviral treatment dispensing in BC HIV Treatment Program

# **CD4 or pVL tested:** participants tested for CD4 or pVL within the past 12 months and 6 months, respectively





4.6 Distribution of Antiretroviral Treatment Prescribers FRASER Health Authority

HSDA of Prescriber Residency	# of Prescribers currently prescribing Antiretroviral Treatment	# of Participants currently treated by Prescribers	# of Prescribers ever prescribed Antiretroviral Treatment	# of Participants ever treated by Prescribers
FRASER EAST	29	66	154	556
FRASER NORTH	28	239	268	1660
FRASER SOUTH	42	552	238	1982
<b>Total:</b>	<b>99</b>	<b>857</b>	<b>660</b>	<b>4198</b>

HSDA of Participant Residency	# of Participants with Prescriber out of HA/HSDA
FRASER EAST	219
FRASER NORTH	735
FRASER SOUTH	477
<b>Total:</b>	<b>1431</b>

\* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

**Currently prescribing Antiretroviral Treatment:** number of prescribers of antiretroviral treatment dispensed in the previous 6 months (based on participant HA/HSDA)

**Currently treated:** number of participants with antiretroviral treatment dispensed in the previous 6 months by antiretroviral treatment prescribers (based on follow-up prescriber HA/HSDA)

**Prescribers ever prescribed Antiretroviral Treatment:** for participants residing in HA/HSDA

**Participants ever treated by prescribers:** where follow-up prescriber is in the HA/HSDA

**Participants with Prescriber out of HA/HSDA:** participants residing in specified HA/HSDA with follow-up prescriber(s) in another HA/HSDA



**4.7 Distribution of Participants by Age & Sex at Birth VANCOUVER COASTAL Health Authority (HA)**

Health Service Delivery Area	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
NORTH SHORE/COAST GARIBALDI	0 - 29	10	10	0	9	920	7	<40
	30 - 49	77	68	0	58	700	65	<40
	50 - 64	131	122	0	82	720	108	<40
	65+	95	90	0	77	670	85	<40
	<b>Total HSDA:</b>	<b>313</b>	<b>290</b>	<b>0</b>	<b>226</b>	<b>700</b>	<b>265</b>	<b>&lt;40</b>
RICHMOND	0 - 29	11	8	*	10	650	8	<40
	30 - 49	63	55	*	55	620	55	<40
	50 - 64	78	74	*	62	670	72	<40
	65+	28	28	*	26	540	26	<40
	<b>Total HSDA:</b>	<b>180</b>	<b>165</b>	<b>&lt;5</b>	<b>153</b>	<b>630</b>	<b>161</b>	<b>&lt;40</b>
VANCOUVER	0 - 29	106	96	*	93	740	94	<40
	30 - 49	1141	1011	*	834	690	969	<40
	50 - 64	1491	1369	*	1022	600	1341	<40
	65+	741	699	*	465	620	699	<40
	<b>Total HSDA:</b>	<b>3479</b>	<b>3175</b>	<b>&lt;5</b>	<b>2414</b>	<b>640</b>	<b>3103</b>	<b>&lt;40</b>
<b>Total HA:</b>		<b>3972</b>	<b>3630</b>	<b>&lt;5</b>	<b>2793</b>	<b>650</b>	<b>3529</b>	<b>&lt;40</b>

	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	0 - 29	127	114	*	112	745	109	<40
	30 - 49	1281	1134	*	947	680	1089	<40
	50 - 64	1700	1565	*	1166	620	1521	<40
	65+	864	817	*	568	630	810	<40
<b>Total HA:</b>		<b>3972</b>	<b>3630</b>	<b>&lt;5</b>	<b>2793</b>	<b>650</b>	<b>3529</b>	<b>&lt;40</b>

Sex at Birth	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
Male	3478	3189	*	2332	640	3108	<40
Female	494	441	*	461	670	421	<40
Unknown	0	0	*	0	N/A	0	N/A

Currently on antiretroviral treatment	# of Participants	Median Age	Median CD4	Median pVL
<b>Total HA:</b>	<b>3630</b>	<b>56</b>	<b>650</b>	<b>&lt;40</b>

\* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

# **Enrolled**: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program  
 # **on ART**: # of participants on antiretroviral treatment (ART) in the specified month based on dispensing record  
 # **CD4** or **pVL** tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ $\mu$ L and pVL in copies/mL)



**4.8 Distribution of Participants by Program Duration VANCOUVER COASTAL Health Authority**

HSDA	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
NORTH SHORE/COAST GARIBALDI	10 years or more	225	207	0	*	*	192	<40
	5 years or more	44	41	0	*	*	38	<40
	<5 years	44	42	0	*	*	35	<40
	Never on ART	0	0	0	*	*	0	N/A
	<b>Total HSDA:</b>	<b>313</b>	<b>290</b>	<b>0</b>	<b>226</b>	<b>700</b>	<b>265</b>	<b>&lt;40</b>
RICHMOND	10 years or more	101	96	*	*	*	*	*
	5 years or more	35	29	*	*	*	*	*
	<5 years	44	40	*	*	*	*	*
	Never on ART	0	0	*	*	*	*	*
	<b>Total HSDA:</b>	<b>180</b>	<b>165</b>	<b>&lt;5</b>	<b>153</b>	<b>630</b>	<b>161</b>	<b>&lt;40</b>
VANCOUVER	10 years or more	2440	2259	*	1621	620	2211	<40
	5 years or more	553	474	*	374	720	447	<40
	<5 years	486	442	*	412	670	438	<40
	Never on ART	0	0	*	7	550	7	<40
	<b>Total HSDA:</b>	<b>3479</b>	<b>3175</b>	<b>&lt;5</b>	<b>2414</b>	<b>640</b>	<b>3103</b>	<b>&lt;40</b>
<b>Total HA:</b>		<b>3972</b>	<b>3630</b>	<b>&lt;5</b>	<b>2793</b>	<b>650</b>	<b>3529</b>	<b>&lt;40</b>

	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	10 years or more	2766	2562	*	1856	630	2493	<40
	5 years or more	632	544	*	435	720	513	<40
	<5 years	574	524	*	493	650	515	<40
	Never on ART	0	0	*	9	550	8	<40
<b>Total HA:</b>		<b>3972</b>	<b>3630</b>	<b>&lt;5</b>	<b>2793</b>	<b>650</b>	<b>3529</b>	<b>&lt;40</b>

\* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

# **Enrolled:** Participants who had enrolled in HIV Treatment Program, not known to be deceased or formally reported as moved out of program

# **on ART:** Participants on antiretroviral treatment (ART) in the specified month based on dispensing record (as above footnote)

**Program Duration:** years since first antiretroviral treatment dispensing in BC HIV Treatment Program

# **CD4 or pVL tested:** participants tested for CD4 or pVL within the past 12 months and 6 months, respectively





4.9 Distribution of Antiretroviral Treatment Prescribers VANCOUVER COASTAL Health Authority

HSDA of Prescriber Residency	# of Prescribers currently prescribing Antiretroviral Treatment	# of Participants currently treated by Prescribers	# of Prescribers ever prescribed Antiretroviral Treatment	# of Participants ever treated by Prescribers
NORTH SHORE/COAST GARIBALDI	37	60	203	581
RICHMOND	9	113	49	343
VANCOUVER	202	5405	700	12233
<b>Total:</b>	<b>248</b>	<b>5578</b>	<b>952</b>	<b>13157</b>

HSDA of Participant Residency	# of Participants with Prescriber out of HA/HSDA
NORTH SHORE/COAST GARIBALDI	12
RICHMOND	5
VANCOUVER	39
<b>Total:</b>	<b>56</b>

\* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

**Currently prescribing Antiretroviral Treatment:** number of prescribers of antiretroviral treatment dispensed in the previous 6 months (based on participant HA/HSDA)

**Currently treated:** number of participants with antiretroviral treatment dispensed in the previous 6 months by antiretroviral treatment prescribers (based on follow-up prescriber HA/HSDA)

**Prescribers ever prescribed Antiretroviral Treatment:** for participants residing in HA/HSDA

**Participants ever treated by prescribers:** where follow-up prescriber is in the HA/HSDA

**Participants with Prescriber out of HA/HSDA:** participants residing in specified HA/HSDA with follow-up prescriber(s) in another HA/HSDA



**4.10 Distribution of Participants by Age & Sex at Birth VANCOUVER ISLAND Health Authority (HA)**

Health Service Delivery Area	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
CENTRAL VANCOUVER ISLAND	0 - 29	8	6	0	5	810	6	<40
	30 - 49	83	79	0	53	630	70	<40
	50 - 64	145	133	0	69	660	117	<40
	65+	89	83	0	40	520	80	<40
	<b>Total HSDA:</b>	<b>325</b>	<b>301</b>	<b>0</b>	<b>167</b>	<b>590</b>	<b>273</b>	<b>&lt;40</b>
NORTH VANCOUVER ISLAND	0 - 29	5	5	0	*	*	*	*
	30 - 49	28	24	0	*	*	*	*
	50 - 64	55	50	0	*	*	*	*
	65+	34	31	0	*	*	*	*
	<b>Total HSDA:</b>	<b>122</b>	<b>110</b>	<b>0</b>	<b>65</b>	<b>650</b>	<b>89</b>	<b>&lt;40</b>
SOUTH VANCOUVER ISLAND	0 - 29	31	28	0	13	510	22	<40
	30 - 49	205	177	0	71	620	164	<40
	50 - 64	310	292	0	94	655	258	<40
	65+	163	161	0	35	700	154	<40
	<b>Total HSDA:</b>	<b>709</b>	<b>658</b>	<b>0</b>	<b>213</b>	<b>650</b>	<b>598</b>	<b>&lt;40</b>
<b>Total HA:</b>		<b>1156</b>	<b>1069</b>	<b>0</b>	<b>445</b>	<b>630</b>	<b>960</b>	<b>&lt;40</b>

	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	0 - 29	44	39	0	22	525	32	<40
	30 - 49	316	280	0	143	630	252	<40
	50 - 64	510	475	0	190	660	414	<40
	65+	286	275	0	90	605	262	<40
<b>Total HA:</b>		<b>1156</b>	<b>1069</b>	<b>0</b>	<b>445</b>	<b>630</b>	<b>960</b>	<b>&lt;40</b>

Sex at Birth	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
Male	964	893	0	350	600	802	<40
Female	192	176	0	95	690	158	<40
Unknown	0	0	0	0	N/A	0	N/A

Currently on antiretroviral treatment	# of Participants	Median Age	Median CD4	Median pVL
<b>Total HA:</b>	<b>1069</b>	<b>58</b>	<b>650</b>	<b>&lt;40</b>

\* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

# **Enrolled**: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program  
 # **on ART**: # of participants on antiretroviral treatment (ART) in the specified month based on dispensing record  
 # **CD4** or **pVL** tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ $\mu$ L and pVL in copies/mL)



**4.11 Distribution of Participants by Program Duration VANCOUVER ISLAND Health Authority**

HSDA	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
CENTRAL VANCOUVER ISLAND	10 years or more	223	203	0	101	590	189	<40
	5 years or more	51	49	0	29	750	43	<40
	<5 years	51	49	0	37	540	41	<40
	Never on ART	0	0	0	0	N/A	0	N/A
	<b>Total HSDA:</b>	<b>325</b>	<b>301</b>	<b>0</b>	<b>167</b>	<b>590</b>	<b>273</b>	<b>&lt;40</b>
NORTH VANCOUVER ISLAND	10 years or more	90	79	0	40	645	66	<40
	5 years or more	13	13	0	8	655	8	<40
	<5 years	19	18	0	17	700	15	<40
	Never on ART	0	0	0	0	N/A	0	N/A
	<b>Total HSDA:</b>	<b>122</b>	<b>110</b>	<b>0</b>	<b>65</b>	<b>650</b>	<b>89</b>	<b>&lt;40</b>
SOUTH VANCOUVER ISLAND	10 years or more	431	411	0	*	*	*	*
	5 years or more	130	113	0	*	*	*	*
	<5 years	148	134	0	*	*	*	*
	Never on ART	0	0	0	*	*	*	*
	<b>Total HSDA:</b>	<b>709</b>	<b>658</b>	<b>0</b>	<b>213</b>	<b>650</b>	<b>598</b>	<b>&lt;40</b>
<b>Total HA:</b>		<b>1156</b>	<b>1069</b>	<b>0</b>	<b>445</b>	<b>630</b>	<b>960</b>	<b>&lt;40</b>

	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	10 years or more	744	693	0	*	*	*	*
	5 years or more	194	175	0	*	*	*	*
	<5 years	218	201	0	*	*	*	*
	Never on ART	0	0	0	*	*	*	*
<b>Total HA:</b>		<b>1156</b>	<b>1069</b>	<b>0</b>	<b>445</b>	<b>630</b>	<b>960</b>	<b>&lt;40</b>

\* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

# **Enrolled:** Participants who had enrolled in HIV Treatment Program, not known to be deceased or formally reported as moved out of program

# **on ART:** Participants on antiretroviral treatment (ART) in the specified month based on dispensing record (as above footnote)

**Program Duration:** years since first antiretroviral treatment dispensing in BC HIV Treatment Program

# **CD4 or pVL tested:** participants tested for CD4 or pVL within the past 12 months and 6 months, respectively





4.12 Distribution of Antiretroviral Treatment Prescribers VANCOUVER ISLAND Health Authority

HSDA of Prescriber Residency	# of Prescribers currently prescribing Antiretroviral Treatment	# of Participants currently treated by Prescribers	# of Prescribers ever prescribed Antiretroviral Treatment	# of Participants ever treated by Prescribers
CENTRAL VANCOUVER ISLAND	66	211	214	982
NORTH VANCOUVER ISLAND	33	66	155	367
SOUTH VANCOUVER ISLAND	47	610	239	2080
<b>Total:</b>	<b>146</b>	<b>887</b>	<b>608</b>	<b>3429</b>

HSDA of Participant Residency	# of Participants with Prescriber out of HA/HSDA
CENTRAL VANCOUVER ISLAND	88
NORTH VANCOUVER ISLAND	50
SOUTH VANCOUVER ISLAND	128
<b>Total:</b>	<b>266</b>

\* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

**Currently prescribing Antiretroviral Treatment:** number of prescribers of antiretroviral treatment dispensed in the previous 6 months (based on participant HA/HSDA)

**Currently treated:** number of participants with antiretroviral treatment dispensed in the previous 6 months by antiretroviral treatment prescribers (based on follow-up prescriber HA/HSDA)

**Prescribers ever prescribed Antiretroviral Treatment:** for participants residing in HA/HSDA

**Participants ever treated by prescribers:** where follow-up prescriber is in the HA/HSDA

**Participants with Prescriber out of HA/HSDA:** participants residing in specified HA/HSDA with follow-up prescriber(s) in another HA/HSDA



**4.13 Distribution of Participants by Age & Sex at Birth NORTHERN Health Authority (HA)**

Health Service Delivery Area	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
NORTH EAST	0 - 29	*	*	0	*	*	*	*
	30 - 49	*	*	0	*	*	*	*
	50 - 64	*	*	0	*	*	*	*
	65+	*	*	0	*	*	*	*
	<b>Total HSDA:</b>	<b>46</b>	<b>35</b>	<b>0</b>	<b>44</b>	<b>545</b>	<b>36</b>	<b>&lt;40</b>
NORTH WEST	0 - 29	*	*	0	*	*	*	*
	30 - 49	*	*	0	*	*	*	*
	50 - 64	*	*	0	*	*	*	*
	65+	*	*	0	*	*	*	*
	<b>Total HSDA:</b>	<b>72</b>	<b>62</b>	<b>0</b>	<b>64</b>	<b>580</b>	<b>60</b>	<b>&lt;40</b>
NORTHERN INTERIOR	0 - 29	7	6	0	7	710	7	<40
	30 - 49	69	55	0	63	670	49	<40
	50 - 64	68	60	0	65	530	53	<40
	65+	34	30	0	34	550	28	<40
	<b>Total HSDA:</b>	<b>178</b>	<b>151</b>	<b>0</b>	<b>169</b>	<b>580</b>	<b>137</b>	<b>&lt;40</b>
<b>Total HA:</b>		<b>296</b>	<b>248</b>	<b>0</b>	<b>277</b>	<b>580</b>	<b>233</b>	<b>&lt;40</b>

	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	0 - 29	13	11	0	13	700	13	<40
	30 - 49	111	88	0	99	650	80	<40
	50 - 64	121	103	0	115	550	97	<40
	65+	51	46	0	50	500	43	<40
<b>Total HA:</b>		<b>296</b>	<b>248</b>	<b>0</b>	<b>277</b>	<b>580</b>	<b>233</b>	<b>&lt;40</b>

Sex at Birth	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
Male	194	161	0	183	590	158	<40
Female	102	87	0	94	560	75	<40
Unknown	0	0	0	0	N/A	0	N/A

Currently on antiretroviral treatment	# of Participants	Median Age	Median CD4	Median pVL
<b>Total HA:</b>	<b>248</b>	<b>54</b>	<b>600</b>	<b>&lt;40</b>

\* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

# **Enrolled**: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program  
 # **on ART**: # of participants on antiretroviral treatment (ART) in the specified month based on dispensing record  
 # **CD4** or **pVL** tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ $\mu$ L and pVL in copies/mL)



**4.14 Distribution of Participants by Program Duration NORTHERN Health Authority**

HSDA	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
NORTH EAST	10 years or more	22	*	0	*	*	*	*
	5 years or more	5	*	0	*	*	*	*
	<5 years	19	*	0	*	*	*	*
	Never on ART	0	*	0	*	*	*	*
	<b>Total HSDA:</b>	<b>46</b>	<b>35</b>	<b>0</b>	<b>44</b>	<b>545</b>	<b>36</b>	<b>&lt;40</b>
NORTH WEST	10 years or more	49	41	0	43	590	40	<40
	5 years or more	8	8	0	6	640	8	<40
	<5 years	15	13	0	15	570	12	<40
	Never on ART	0	0	0	0	N/A	0	N/A
	<b>Total HSDA:</b>	<b>72</b>	<b>62</b>	<b>0</b>	<b>64</b>	<b>580</b>	<b>60</b>	<b>&lt;40</b>
NORTHERN INTERIOR	10 years or more	116	101	0	*	*	*	*
	5 years or more	36	29	0	*	*	*	*
	<5 years	26	21	0	*	*	*	*
	Never on ART	0	0	0	*	*	*	*
	<b>Total HSDA:</b>	<b>178</b>	<b>151</b>	<b>0</b>	<b>169</b>	<b>580</b>	<b>137</b>	<b>&lt;40</b>
<b>Total HA:</b>		<b>296</b>	<b>248</b>	<b>0</b>	<b>277</b>	<b>580</b>	<b>233</b>	<b>&lt;40</b>

	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	10 years or more	187	157	0	*	*	*	*
	5 years or more	49	39	0	*	*	*	*
	<5 years	60	52	0	*	*	*	*
	Never on ART	0	0	0	*	*	*	*
<b>Total HA:</b>		<b>296</b>	<b>248</b>	<b>0</b>	<b>277</b>	<b>580</b>	<b>233</b>	<b>&lt;40</b>

\* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

# **Enrolled:** Participants who had enrolled in HIV Treatment Program, not known to be deceased or formally reported as moved out of program

# **on ART:** Participants on antiretroviral treatment (ART) in the specified month based on dispensing record (as above footnote)

**Program Duration:** years since first antiretroviral treatment dispensing in BC HIV Treatment Program

# **CD4 or pVL tested:** participants tested for CD4 or pVL within the past 12 months and 6 months, respectively





4.15 Distribution of Antiretroviral Treatment Prescribers NORTHERN Health Authority

HSDA of Prescriber Residency	# of Prescribers currently prescribing Antiretroviral Treatment	# of Participants currently treated by Prescribers	# of Prescribers ever prescribed Antiretroviral Treatment	# of Participants ever treated by Prescribers
NORTH EAST	2	*	37	50
NORTH WEST	15	*	93	177
NORTHERN INTERIOR	21	*	129	555
<b>Total:</b>	<b>38</b>	<b>222</b>	<b>259</b>	<b>782</b>

HSDA of Participant Residency	# of Participants with Prescriber out of HA/HSDA
NORTH EAST	8
NORTH WEST	29
NORTHERN INTERIOR	23
<b>Total:</b>	<b>60</b>

\* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

**Currently prescribing Antiretroviral Treatment:** number of prescribers of antiretroviral treatment dispensed in the previous 6 months (based on participant HA/HSDA)

**Currently treated:** number of participants with antiretroviral treatment dispensed in the previous 6 months by antiretroviral treatment prescribers (based on follow-up prescriber HA/HSDA)

**Prescribers ever prescribed Antiretroviral Treatment:** for participants residing in HA/HSDA

**Participants ever treated by prescribers:** where follow-up prescriber is in the HA/HSDA

**Participants with Prescriber out of HA/HSDA:** participants residing in specified HA/HSDA with follow-up prescriber(s) in another HA/HSDA



**4.16 Distribution of Indigenous Participants by Health Service Delivery Area and Sex at Birth**

HA	HSDA	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
INTERIOR	EAST KOOTENAY	*	*	0	*	*	*	*
	KOOTENAY BOUNDARY	*	*	0	*	*	*	*
	OKANAGAN	*	*	0	*	*	*	*
	THOMPSON/CARIBOO/SHUSWAP	*	*	0	*	*	*	*
	<b>Total HA:</b>	<b>53</b>	<b>46</b>	<b>0</b>	<b>43</b>	<b>550</b>	<b>38</b>	<b>&lt;40</b>
FRASER	FRASER EAST	30	27	0	24	615	24	<40
	FRASER NORTH	41	35	0	30	470	31	<40
	FRASER SOUTH	62	57	0	41	570	52	<40
	<b>Total HA:</b>	<b>133</b>	<b>119</b>	<b>0</b>	<b>95</b>	<b>558</b>	<b>107</b>	<b>&lt;40</b>
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	29	27	0	23	780	20	<40
	RICHMOND	6	6	0	6	775	6	<40
	VANCOUVER	361	330	0	342	480	317	<40
	<b>Total HA:</b>	<b>396</b>	<b>363</b>	<b>0</b>	<b>371</b>	<b>500</b>	<b>343</b>	<b>&lt;40</b>
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	44	40	0	24	550	34	<40
	NORTH VANCOUVER ISLAND	16	13	0	11	440	10	<40
	SOUTH VANCOUVER ISLAND	44	39	0	15	590	35	<40
	<b>Total HA:</b>	<b>104</b>	<b>92</b>	<b>0</b>	<b>50</b>	<b>555</b>	<b>79</b>	<b>&lt;40</b>
NORTHERN	NORTH EAST	11	8	0	11	450	7	<40
	NORTH WEST	33	27	0	30	515	27	<40
	NORTHERN INTERIOR	65	56	0	61	570	51	<40
	<b>Total HA:</b>	<b>109</b>	<b>91</b>	<b>0</b>	<b>102</b>	<b>560</b>	<b>85</b>	<b>&lt;40</b>
<b>Total:</b>	<b>795</b>	<b>711</b>	<b>0</b>	<b>661</b>	<b>530</b>	<b>652</b>	<b>&lt;40</b>	

Sex at Birth	# Enrolled	# on Antiretroviral Treatment	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
Male	499	448	0	407	510	412	<40
Female	296	263	0	254	559	240	<40
Unknown	0	0	0	0	N/A	0	N/A

Currently on antiretroviral treatment	# of Participants	Median Age	Median CD4	Median pVL
<b>Total:</b>	<b>711</b>	<b>55</b>	<b>540</b>	<b>&lt;40</b>

\* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

# **Enrolled:** Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program

# **on Antiretroviral Treatment:** defined as # of Participants being on antiretroviral treatment in the specified month

# **CD4 or pVL tested:** participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/μL and pVL in copies/mL)





BRITISH COLUMBIA  
CENTRE *for* EXCELLENCE  
*in* HIV/AIDS

---

Funding for the BC Centre for Excellence in HIV/AIDS and HIV Drug Treatment Program provided in-part by:

